Immunome (IMNM) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free IMNM Stock Alerts $13.83 -0.57 (-3.96%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 4:18 AM | americanbankingnews.comImmunome (NASDAQ:IMNM) Shares Down 4% May 18 at 5:36 AM | americanbankingnews.comFY2024 Earnings Estimate for Immunome, Inc. (NASDAQ:IMNM) Issued By Leerink PartnrsMay 18 at 5:36 AM | americanbankingnews.comImmunome, Inc. (NASDAQ:IMNM) to Post FY2024 Earnings of ($2.02) Per Share, Wedbush ForecastsMay 17 at 1:54 PM | marketbeat.comImmunome (NASDAQ:IMNM) Stock Price Down 4%Immunome (NASDAQ:IMNM) Shares Down 4%May 17 at 9:57 AM | msn.comImmunome appoints CFOMay 17 at 8:59 AM | marketbeat.comImmunome, Inc. to Post FY2024 Earnings of ($0.76) Per Share, Leerink Partnrs Forecasts (NASDAQ:IMNM)Immunome, Inc. (NASDAQ:IMNM - Free Report) - Investment analysts at Leerink Partnrs boosted their FY2024 earnings per share estimates for shares of Immunome in a research note issued on Tuesday, May 14th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($0.76)May 17 at 8:00 AM | businesswire.comImmunome Announces Promotion of Max Rosett to Chief Financial OfficerMay 17 at 2:12 AM | americanbankingnews.comWedbush Weighs in on Immunome, Inc.'s Q2 2024 Earnings (NASDAQ:IMNM)May 16, 2024 | markets.businessinsider.comImmunome’s Promising Pipeline and Strategic Positioning Affirm Buy RatingMay 16, 2024 | marketbeat.comQ2 2024 Earnings Forecast for Immunome, Inc. (NASDAQ:IMNM) Issued By WedbushImmunome, Inc. (NASDAQ:IMNM - Free Report) - Analysts at Wedbush lowered their Q2 2024 earnings estimates for shares of Immunome in a report released on Tuesday, May 14th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.57) for the quarter, downMay 15, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Up 5.6%Immunome (NASDAQ:IMNM) Shares Up 5.6%May 15, 2024 | americanbankingnews.comImmunome (NASDAQ:IMNM) Stock Rating Reaffirmed by WedbushMay 14, 2024 | marketbeat.comImmunome's (IMNM) "Outperform" Rating Reaffirmed at WedbushWedbush reissued an "outperform" rating and set a $33.00 price target on shares of Immunome in a research report on Tuesday.May 14, 2024 | investorplace.comIMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024May 14, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Gap Down to $15.61Immunome (NASDAQ:IMNM) Shares Gap Down to $15.61May 14, 2024 | markets.businessinsider.comImmunome, Inc. Q1 Loss Increases, Misses EstimatesMay 14, 2024 | businesswire.comImmunome Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 11, 2024 | americanbankingnews.comComparing GlobeStar Therapeutics (OTCMKTS:GSTC) and Immunome (NASDAQ:IMNM)May 10, 2024 | americanbankingnews.comImmunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of "Buy" from AnalystsMay 8, 2024 | businesswire.comImmunome to Present at 2024 Bank of America Healthcare ConferenceMay 2, 2024 | businesswire.comImmunome Appoints Kinney Horn as Chief Business OfficerApril 30, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Gap Up to $13.82Immunome (NASDAQ:IMNM) Shares Gap Up to $13.82April 25, 2024 | businesswire.comImmunome Appoints Sandra M. Swain to Board of DirectorsApril 24, 2024 | marketbeat.com61,346 Shares in Immunome, Inc. (NASDAQ:IMNM) Acquired by Cerity Partners LLCCerity Partners LLC purchased a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 61,346 shares of the company's stock, valueApril 22, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Gap Up to $15.48Immunome (NASDAQ:IMNM) Shares Gap Up to $15.48April 19, 2024 | finance.yahoo.comImmunome, Inc. (IMNM)April 17, 2024 | msn.comImmunome (IMNM) Price Target Increased by 8.72% to 36.04April 16, 2024 | msn.comGuggenheim Initiates Coverage of Immunome (IMNM) with Buy RecommendationApril 15, 2024 | marketbeat.comEmfo LLC Buys Shares of 59,165 Immunome, Inc. (NASDAQ:IMNM)Emfo LLC bought a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 59,165 shares of the company's stock, valued at approximately $633,000. Emfo LLC owned approximately 0.14% ofApril 15, 2024 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Given Average Rating of "Buy" by BrokeragesShares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have received a consensus rating of "Buy" from the five ratings firms that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers thaApril 5, 2024 | businesswire.comImmunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual MeetingApril 4, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Trading Down 4.5%Immunome (NASDAQ:IMNM) Trading Down 4.5%April 4, 2024 | marketbeat.comQ1 2024 EPS Estimates for Immunome, Inc. (NASDAQ:IMNM) Reduced by WedbushImmunome, Inc. (NASDAQ:IMNM - Free Report) - Stock analysts at Wedbush dropped their Q1 2024 earnings estimates for shares of Immunome in a research note issued on Monday, April 1st. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($0.52) per share for the quarter, downApril 3, 2024 | marketbeat.comWedbush Weighs in on Immunome, Inc.'s Q1 2025 Earnings (NASDAQ:IMNM)Immunome, Inc. (NASDAQ:IMNM - Free Report) - Investment analysts at Wedbush issued their Q1 2025 earnings estimates for shares of Immunome in a research report issued on Monday, April 1st. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.78) per share for theApril 1, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Given New $33.00 Price Target at WedbushWedbush lifted their target price on shares of Immunome from $27.00 to $33.00 and gave the stock an "outperform" rating in a research note on Monday.March 29, 2024 | marketbeat.comLeerink Partnrs Weighs in on Immunome, Inc.'s Q1 2024 Earnings (NASDAQ:IMNM)Immunome, Inc. (NASDAQ:IMNM - Free Report) - Leerink Partnrs lifted their Q1 2024 EPS estimates for Immunome in a research note issued to investors on Tuesday, March 26th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($1.71) for the quarter, upMarch 29, 2024 | investorplace.comIMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023March 28, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Immunome (IMNM)March 28, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Down 3.7% Immunome (NASDAQ:IMNM) Stock Price Down 3.7%March 28, 2024 | businesswire.comImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired AssetsMarch 28, 2024 | businesswire.comImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired AssetsMarch 27, 2024 | finance.yahoo.comImmunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From AyalaMarch 26, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Up 5.3%Immunome (NASDAQ:IMNM) Trading Up 5.3%March 22, 2024 | finance.yahoo.comImmunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutionsMarch 20, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Trading Down 5%Immunome (NASDAQ:IMNM) Shares Down 5%March 19, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Trading 7.3% Higher Immunome (NASDAQ:IMNM) Shares Up 7.3%March 18, 2024 | msn.comArrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapiesMarch 18, 2024 | businesswire.comArrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer TherapiesMarch 11, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Down 6.3% Immunome (NASDAQ:IMNM) Trading Down 6.3%March 7, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Sets New 1-Year High at $29.40Immunome (NASDAQ:IMNM) Reaches New 52-Week High at $29.40 Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now IMNM Media Mentions By Week IMNM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMNM News Sentiment▼0.380.42▲Average Medical News Sentiment IMNM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMNM Articles This Week▼282▲IMNM Articles Average Week Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ABVX News Today ETNB News Today SPRY News Today OPK News Today CNTA News Today PLRX News Today LQDA News Today ZNTL News Today OCUL News Today ARQT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMNM) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
